ArticleeLife2024
Inclusive, exclusive and hierarchical atlas of NFATc1
Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The zig-zag model of molecular defense and counterdefense in plant-herbivore interactions.Planta · 2026Review
- Platelet-derived concentrates in the immunological management of periodontitis: from dysbiosis to personalized approaches.Odontology · 2026Review
- NFATC1 dysfunction-triggered MSC senescence induces tooth aging amenable to senolytic therapy.Stem cell reports · 2026Article
- PDGFRα-positive mesenchymal stem/stromal cells contribute to autonomous vascular formation through in-body tissue architecture.PloS one · 2026Article
- Single-cell RNA sequencing reveals NFATc1-mediated regulatory mechanisms of vascular smooth muscle cell osteogenic transformation in the osteosarcoma microenvironment.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Platelet-derived growth factor receptor alpha (PDGFR-α) activity is crucial in the process of dental and periodontal mesenchyme regeneration facilitated by autologous platelet concentrates (APCs), such as platelet-rich fibrin (PRF), platelet-rich plasma (PRP) and concentrated growth factors (CGF), as well as by recombinant PDGF drugs. However, it is largely unclear about the physiological patterns and cellular fate determinations of PDGFR-α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.